Cohort I baseline characteristics overall and by inclusion in the analysis of HIV diversity.

<p>The table shows baseline demographic and clinical characteristics for children who were enrolled in Cohort I of the P1060 study and were vs. were not included in the analysis of HIV diversity (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0081213#pone-0081213-g001" target="_blank">Figure 1</a>). P values <0.05 are bolded. Abbreviations: S Africa: South Africa; NVP: nevirapine; LPV/r: lopinavir/ritonavir; m: months; WHO: World Health Organization; sd: standard deviation; HIV RNA: expressed as log₁₀ copies/mL; CD4 cell count: expressed as cells/mm³; CD4%: CD4 cell percentage; ARV: antiretroviral.</p>a<p>Fisher's Exact Test.</p>b<p>Wilcoxon Test.</p>c<p>Maternal ARV drug use during pregnancy was reported for 48 infants; 47 women had used zidovudine (three had also used lamivudine [3TC]) and 1 had used 3TC and stavudine.</p>d<p>Twenty of the 139 infants in this study had ARV resistance at study entry; 15 had resistance to nevirapine (NVP), two had resistance to didanosine (ddI), two had resistance to NVP and ddI, and one had resistance to 3TC and emtricitabine.